Clinical trial
An Open-label Study to Evaluate the Safety and Pharmacokinetics of Migalastat HCl in Subjects With Fabry Disease and Amenable GLA Variants and Severe Renal Impairment or End-Stage Renal Disease Treated With Hemodialysis
NCT04020055 is registered in ClinicalTrials.gov with Amicus Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label Study to Evaluate the Safety and Pharmacokinetics of Migalastat HCl in Subjects With Fabry Disease and Amenable GLA Variants and Severe Renal Impairment or End-Stage Renal Disease Treated With Hemodialysis
- Lead sponsor
- Amicus Therapeutics
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- October 31, 2022
- Completion date
- December 31, 2026
- Enrollment
- 14 (estimated)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.